According to Sandoz, Ireland and the Czech Republic have approved marketing applications for the AirFluSal Forspiro salmeterol/fluticasone DPI in 50-250 and 50-500 µg dosage forms for the treatment of asthma and/or COPD. The Czech approval triggers a €1.5 million milestone payment from Sandoz to Vectura.
Sandoz Head of Global Respiratory Jan-Torsten Tews said, “We look forward to continuing our European and global market roll-out of AirFluSal Forspiro and making it available to a steadily growing number of people suffering from asthma and COPD. This is an affordable and award winning new therapeutic option, developed in close collaboration with patients.”
The product is now approved in a total of 17 countries and has been launched in 5.
Read the Sandoz press release.
